These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment. Ruigrok EAM; Verkaik NS; de Blois E; de Ridder C; Stuurman D; Roobol SJ; Van Gent DC; de Jong M; Van Weerden WM; Nonnekens J Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887398 [TBL] [Abstract][Full Text] [Related]
9. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction. Stingl L; Stühmer T; Chatterjee M; Jensen MR; Flentje M; Djuzenova CS Br J Cancer; 2010 May; 102(11):1578-91. PubMed ID: 20502461 [TBL] [Abstract][Full Text] [Related]
10. DNA topoisomerase I-targeting drugs as radiation sensitizers. Chen AY; Choy H; Rothenberg ML Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):39-46. PubMed ID: 10550825 [TBL] [Abstract][Full Text] [Related]
11. [Targeted therapies and radiation therapy in non-small cell lung cancer]. Rivera S; Quéro L; Wong Hee Kam S; Maylin C; Deutsch E; Hennequin C Cancer Radiother; 2011 Oct; 15(6-7):527-35. PubMed ID: 21885318 [TBL] [Abstract][Full Text] [Related]
12. Combination Therapy, a Promising Approach to Enhance the Efficacy of Radionuclide and Targeted Radionuclide Therapy of Prostate and Breast Cancer. Damiana TST; Dalm SU Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34067215 [TBL] [Abstract][Full Text] [Related]
13. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition. Gabbasov R; Benrubi ID; O'Brien SW; Krais JJ; Johnson N; Litwin S; Connolly DC Cancer Biol Ther; 2019; 20(7):1035-1045. PubMed ID: 30929564 [TBL] [Abstract][Full Text] [Related]
14. Imaging DNA Damage Repair In Vivo After O'Neill E; Kersemans V; Allen PD; Terry SYA; Torres JB; Mosley M; Smart S; Lee BQ; Falzone N; Vallis KA; Konijnenberg MW; de Jong M; Nonnekens J; Cornelissen B J Nucl Med; 2020 May; 61(5):743-750. PubMed ID: 31757844 [TBL] [Abstract][Full Text] [Related]
15. Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer. Alcorn S; Walker AJ; Gandhi N; Narang A; Wild AT; Hales RK; Herman JM; Song DY; Deweese TL; Antonarakis ES; Tran PT Int J Mol Sci; 2013 Jul; 14(7):14800-32. PubMed ID: 23863691 [TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608 [TBL] [Abstract][Full Text] [Related]
17. Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic. Bellavia MC; Patel RB; Anderson CJ J Nucl Med; 2022 Nov; 63(11):1636-1641. PubMed ID: 36215570 [TBL] [Abstract][Full Text] [Related]
18. [Inhibitors of the heat shock protein 90 activity: a novel class of tumor radiosensitizers]. Kabakov AE; Kudriavtsev VA; Makarova IuM Radiats Biol Radioecol; 2010; 50(5):528-35. PubMed ID: 21261003 [TBL] [Abstract][Full Text] [Related]
19. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage. Ha K; Fiskus W; Rao R; Balusu R; Venkannagari S; Nalabothula NR; Bhalla KN Mol Cancer Ther; 2011 Jul; 10(7):1194-206. PubMed ID: 21566061 [TBL] [Abstract][Full Text] [Related]
20. Strategizing the clone wars: pharmacological control of cellular sensitivity to radiation. Kimple RJ Mol Interv; 2010 Dec; 10(6):341-53. PubMed ID: 21263160 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]